✦ LIBER ✦

379 POSTER A phase I study of XL184, a MET, VEGFR2, and RET kinase inhibitor, administered orally to patients (pts) with advanced malignancies, including a subgroup of pts with medullary thyroid cancer (MTC)

✍ Scribed by R. Kurzrock; S. Sherman; D. Hong; C. Ng; J. Frye; L. Janisch; M.J. Ratain; R. Salgia

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

405 POSTER A phase I dose-escalation stu

✍ R. Kurzrock; L. Camacho; D. Hong; C. Ng; L. Janisch; M.J. Ratain; R. Salgia 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 90 KB

383 POSTER A phase 1 study of XL281, a p

✍ G.K. Schwartz; S. Yazji; D.S. Mendelson; M.A. Dickson; S.H. Johnston; E.W. Wang; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 56 KB

342 POSTER A phase I dose-escalation and

✍ B.I. Sikic; H.A. Wakelee; A.A. Adjei; J. Halsey; J.L. Lensing; J.D. Dugay; L.J. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 68 KB

83 POSTER A phase I study examining week

✍ M. Mita; J. Cooper; A. Ricart; A. Mita; C. Takimoto; S. Britt; A. Tolcher; A. Do 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 60 KB